Andere Sprachen Cassava Sciences, Inc.

Aktien

A2PGL8

US14817C1071

SAVA

Realtime-Estimate Cboe BZX Andere Börsenplätze 17:57:33 01.05.2024			% 5 Tage	% 1. Jan.
22,08 ^USD	-0,32 %		+6,61 %	-1,78 %

25.03.	Cassava Sciences meldet den Abschluss der Zwischenprüfung der Sicherheit des Alzheimer-Medikamentenkandidaten Simufilam	MT
25.03.	Cassava Sciences, Inc. gibt den Abschluss einer vorläufigen Sicherheitsüberprüfung der laufenden Phase-3-Studien mit oralem Simufilam bekannt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ	15:10
North American Morning Briefing : Investors Brace -2-	29.04.
Cassava Sciences : Corporate Presentation – Second Quarter 2024	24.04.
Cassava Sciences, Inc. - Redemption Date Announced for Warrants	16.04.
Redemption Date Announced for Warrants	15.04.
Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava	29.03.
ROSEN, A LONGSTANDING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important April 2 Deadline in Securities Class Action - SAVA	27.03.
Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA	27.03.
Cassava Sciences Announces Completion of Interim Safety Review for Alzheimer's Drug Candidate Simufilam	25.03.
Cassava Sciences : Corporate Presentation – First Quarter 2024	25.03.
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials	25.03.
Cassava Sciences, Inc. Announces Completion of an Interim Safety Review of Oral Simufilam On-Going Phase 3 Trials	25.03.
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava	21.03.
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SAVA	20.03.
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SAVA	19.03.
Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA	19.03.
ROSEN, A TOP RANKED LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SAVA	17.03.
ROSEN, A LEADING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SAVA	15.03.
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava	13.03.
Thinking about buying stock in Lexicon Pharmaceuticals, Cassava Sciences, Clearside Biomedical, Lantern Pharma, or ATAI Life Sciences?	13.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Cassava Sciences, Inc.

Aktien

A2PGL8

US14817C1071

SAVA

Andere Sprachen

Filter